Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

D Kavanagh; G Ardissino; V Brocklebank; R N Bouwmeester; A Bagga; R Ter Heine; S Johnson; C Licht; A L T Ma; M Noris; M Praga; E Rondeau; A Sinha; R J H Smith; N S Sheerin; H Trimarchi; J F M Wetzels; M Vivarelli; N C A J Van de Kar; L A Greenbaum; Forum Participants; Sjoerd Timmermans

doi:10.1016/j.kint.2024.09.012

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

D Kavanagh^*, G Ardissino, V Brocklebank, R N Bouwmeester, A Bagga, R Ter Heine, S Johnson, C Licht, A L T Ma, M Noris, M Praga, E Rondeau, A Sinha, R J H Smith, N S Sheerin, H Trimarchi, J F M Wetzels, M Vivarelli, N C A J Van de Kar, L A GreenbaumForum Participants, Sjoerd Timmermans

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.

Original language	English
Pages (from-to)	1038-1050
Number of pages	13
Journal	Kidney International
Volume	106
Issue number	6
DOIs	https://doi.org/10.1016/j.kint.2024.09.012
Publication status	Published - Dec 2024

Keywords

XXXX

Access to Document

10.1016/j.kint.2024.09.012Licence: CC BY

Cite this

Kavanagh, D., Ardissino, G., Brocklebank, V., Bouwmeester, R. N., Bagga, A., Ter Heine, R., Johnson, S., Licht, C., Ma, A. L. T., Noris, M., Praga, M., Rondeau, E., Sinha, A., Smith, R. J. H., Sheerin, N. S., Trimarchi, H., Wetzels, J. F. M., Vivarelli, M., Van de Kar, N. C. A. J., ... Timmermans, S. (2024). Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum. Kidney International, 106(6), 1038-1050. https://doi.org/10.1016/j.kint.2024.09.012

@article{a649fbe409524b47ac00d9b7215da770,

title = "Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum",

abstract = "Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.",

keywords = "XXXX",

author = "D Kavanagh and G Ardissino and V Brocklebank and Bouwmeester, \{R N\} and A Bagga and \{Ter Heine\}, R and S Johnson and C Licht and Ma, \{A L T\} and M Noris and M Praga and E Rondeau and A Sinha and Smith, \{R J H\} and Sheerin, \{N S\} and H Trimarchi and Wetzels, \{J F M\} and M Vivarelli and \{Van de Kar\}, \{N C A J\} and Greenbaum, \{L A\} and \{Forum Participants\} and Sjoerd Timmermans",

year = "2024",

month = dec,

doi = "10.1016/j.kint.2024.09.012",

language = "English",

volume = "106",

pages = "1038--1050",

journal = "Kidney International",

issn = "0085-2538",

publisher = "Elsevier B.V.",

number = "6",

}

Kavanagh, D, Ardissino, G, Brocklebank, V, Bouwmeester, RN, Bagga, A, Ter Heine, R, Johnson, S, Licht, C, Ma, ALT, Noris, M, Praga, M, Rondeau, E, Sinha, A, Smith, RJH, Sheerin, NS, Trimarchi, H, Wetzels, JFM, Vivarelli, M, Van de Kar, NCAJ, Greenbaum, LA, Forum Participants & Timmermans, S 2024, 'Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum', Kidney International, vol. 106, no. 6, pp. 1038-1050. https://doi.org/10.1016/j.kint.2024.09.012

TY - JOUR

T1 - Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

AU - Kavanagh, D

AU - Ardissino, G

AU - Brocklebank, V

AU - Bouwmeester, R N

AU - Bagga, A

AU - Ter Heine, R

AU - Johnson, S

AU - Licht, C

AU - Ma, A L T

AU - Noris, M

AU - Praga, M

AU - Rondeau, E

AU - Sinha, A

AU - Smith, R J H

AU - Sheerin, N S

AU - Trimarchi, H

AU - Wetzels, J F M

AU - Vivarelli, M

AU - Van de Kar, N C A J

AU - Greenbaum, L A

AU - Forum Participants

AU - Timmermans, Sjoerd

PY - 2024/12

Y1 - 2024/12

N2 - Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.

AB - Hemolytic uremic syndromes (HUSs) are a heterogeneous group of conditions, only some of which are mediated by complement (complement-mediated HUS). We report the outcome of the 2023 International Society of Nephrology HUS International Forum where a global panel of experts considered the current state of the art, identified areas of uncertainty, and proposed optimal solutions. Areas of uncertainty and areas for future research included the nomenclature of HUS, novel complement testing strategies, identification of biomarkers, genetic predisposition to atypical HUS, optimal dosing and withdrawal strategies for C5 inhibitors, treatment of kidney transplant recipients, disparity of access to treatment, and the next generation of complement inhibitors in complement-mediated HUS. The current rationale for optimal patient management is described.

KW - XXXX

U2 - 10.1016/j.kint.2024.09.012

DO - 10.1016/j.kint.2024.09.012

M3 - Article

SN - 0085-2538

VL - 106

SP - 1038

EP - 1050

JO - Kidney International

JF - Kidney International

IS - 6

ER -

Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum

Abstract

Keywords

Access to Document

Fingerprint

Cite this